In humanized models, breast cancer CD4+ T cells have been shown to inhibit tumour growth by arresting cancer cell cycle progression at the G1/S phase, while simultaneously enhancing antitumour immunity through the activation of pro‐inflammatory signalling pathways. The gene discussed is CD4; the disease is neoplasm.